Skip to main content

Advertisement

ADVERTISEMENT

News

News
06/27/2022
Investigators set out to validate a single-item 7-point indicator to better define a flare of inflammatory bowel disease.
Investigators set out to validate a single-item 7-point indicator to better define a flare of inflammatory bowel disease.
Investigators set out to...
06/27/2022
Advances in Inflammatory Bowel Disease Network

Advertisement

News
06/17/2022
The US Food and Drug Association has approved the interleukin-23 inhibitor risankizumab for the treatment of adults with moderate-to-severe Crohn disease.
The US Food and Drug Association has approved the interleukin-23 inhibitor risankizumab for the treatment of adults with moderate-to-severe Crohn disease.
The US Food and Drug Association...
06/17/2022
Advances in Inflammatory Bowel Disease Network
News
06/10/2022
Tumor necrosis factor inhibitors adalimumab and infliximab achieved significantly higher rates of 1-year endoscopic healing of Crohn disease than vedolizumab or ustekinumab in a new analysis.
Tumor necrosis factor inhibitors adalimumab and infliximab achieved significantly higher rates of 1-year endoscopic healing of Crohn disease than vedolizumab or ustekinumab in a new analysis.
Tumor necrosis factor inhibitors...
06/10/2022
Advances in Inflammatory Bowel Disease Network
News
06/03/2022
Patients with inflammatory bowel disease have higher rates of depression and anxiety, yet fail to complete adequate treatment with antidepressants, investigators found.
Patients with inflammatory bowel disease have higher rates of depression and anxiety, yet fail to complete adequate treatment with antidepressants, investigators found.
Patients with inflammatory bowel...
06/03/2022
Advances in Inflammatory Bowel Disease Network

Advertisement

News
05/11/2022
A new-user study of older patients with inflammatory bowel disease sought to fill knowledge gaps related to the comparative safety and efficacy of vedolizumab and tumor necrosis factor inhibitors among these patients.
A new-user study of older patients with inflammatory bowel disease sought to fill knowledge gaps related to the comparative safety and efficacy of vedolizumab and tumor necrosis factor inhibitors among these patients.
A new-user study of older...
05/11/2022
Advances in Inflammatory Bowel Disease Network
News
04/21/2022
Pediatric patients with inflammatory bowel disease treated with the interleukin 12/23 inhibitor had more than twice the rate of resolution of skin reactions as those who continued on anti-tumor necrosis factor therapy.
Pediatric patients with inflammatory bowel disease treated with the interleukin 12/23 inhibitor had more than twice the rate of resolution of skin reactions as those who continued on anti-tumor necrosis factor therapy.
Pediatric patients with...
04/21/2022
Advances in Inflammatory Bowel Disease Network
News
04/14/2022
Researchers conducting a meta-analysis of studies found an increased rate of cancer among patients with pediatric-onset IBD; however, the overall incidence rate of cancer in this population is low.
Researchers conducting a meta-analysis of studies found an increased rate of cancer among patients with pediatric-onset IBD; however, the overall incidence rate of cancer in this population is low.
Researchers conducting a...
04/14/2022
Advances in Inflammatory Bowel Disease Network

Advertisement

News
04/11/2022
Researchers compared results from randomized clinical trials to determine if men and women have significant differences in response to anti-tumor necrosis factor therapies for ulcerative colitis.
Researchers compared results from randomized clinical trials to determine if men and women have significant differences in response to anti-tumor necrosis factor therapies for ulcerative colitis.
Researchers compared results...
04/11/2022
Advances in Inflammatory Bowel Disease Network
News
03/30/2022
A post-hoc analysis of data from the UNIFI trial showed improvement of symptoms among patients with ulcerative colitis in as few as 7 days.
A post-hoc analysis of data from the UNIFI trial showed improvement of symptoms among patients with ulcerative colitis in as few as 7 days.
A post-hoc analysis of data from...
03/30/2022
Advances in Inflammatory Bowel Disease Network
News
03/28/2022
Large retrospective study finds patients with Crohn disease have higher risk for chronic obstructive pulmonary disease, while those with ulcerative colitis have more pulmonary vasculitis.
Large retrospective study finds patients with Crohn disease have higher risk for chronic obstructive pulmonary disease, while those with ulcerative colitis have more pulmonary vasculitis.
Large retrospective study finds...
03/28/2022
Advances in Inflammatory Bowel Disease Network

Advertisement

Advertisement